Assessment of fecal calprotectin, a surrogate marker of mucosal inflammation, is a promising means to monitor therapeutic response in pediatric inflammatory bowel disease, especially if the result is readily available. We tested the performance of a novel calprotectin rapid test, Quantum Blue, versus the conventional enzyme-linked immunosorbent assay in 134 stool samples from 56 pediatric patients with Crohn disease. The intraclass correlation coefficient analysis reflected good agreement (intraclass correlation coefficient 0.97 [95% confidence interval 0.95-0.98]) but agreement was better in lower values, where dilutions were not required. Using a cutoff of 100μg/g for normal values, the percentage agreement between the 2 tests was 87%. The optimal cutoff values to guide clinical decisions in the therapy of inflammatory bowel disease have yet to be determined. Copyright

Fecal biomarkers, Inflammatory bowel disease, Pediatric
dx.doi.org/10.1097/MPG.0b013e318253cff1, hdl.handle.net/1765/68269
Journal of Pediatric Gastroenterology and Nutrition
Department of Pediatrics

Kolho, K.-L, Turner, D, Veereman-Wauters, G, Sładek, M, de Ridder, L, Shaoul, R, … Veres, G. (2012). Rapid test for fecal calprotectin levels in children with Crohn disease. Journal of Pediatric Gastroenterology and Nutrition, 55(4), 436–439. doi:10.1097/MPG.0b013e318253cff1